Back to Market返回行情

HQL Tekla Life Sciences Investors

USFinancial Services
$20.83+1.26%ClosedMarket Cap: $633.4M

As of 2026-07-09 16:00

Why HQL matters now

Tekla Life Sciences Investors (HQL) is a US stock in Financial Services. The latest InvestLog snapshot shows $20.83 with +1.26% on the session and $633.4M in market capitalization; recent performance reads 1-month +3.16% and YTD +7.03%.

The latest financial table shown here is Q2 2026, with revenue of $48.1M, net income of $65.3M, and EPS of $2.15. Investors can compare that operating picture with valuation signals such as P/E 2.90 and FCF yield -0.5%.

The latest indexable market news headline is "HQL: Attractive Outlook With Growth Of GLP-1 Market" from Seeking Alpha.

Additional event context on this page matters because analyst consensus is available with a median target of $—; recent insider activity includes Mahai Chris LaVictoire filing . These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

2.90

PEG

0.01

P/B

0.97

P/S

9.15

EV/EBITDA

2.76

DCF Value

$89.53

FCF Yield

-0.5%

Div Yield

11.4%

Margins & Returns

Gross Margin

90.7%

Operating Margin

331.9%

Net Margin

331.9%

ROE

36.9%

ROA

35.2%

ROIC

35.2%

Financials

PeriodRevenueNet IncomeEPS
Q2 2026$48.1M$65.3M$2.15
Q4 2025$11.6M$132.8M$4.60
FY 2025$86.4M$85.6M$2.96
Q2 2025$18.2M$-47.2M$-1.64

Analyst Ratings

Consensus

Target (Consensus)

$—

Target (Median)

$—

Target Range

$— - $—

Strong Buy: 0Buy: 0Hold: 0Sell: 0Strong Sell: 0

Trading Activity

Insider Trades

Mahai Chris LaVictoiredirector:
Sell2026-06-11
Reilly Heather Carterofficer
Sell2025-12-19
Pittard Christiandirector
Buy2025-12-18

Company Info

Sector

Financial Services

Industry

Asset Management

Country

US

Exchange

Beta

0.73

Tekla Life Sciences Investors, a closed-ended equity mutual fund, is expertly managed by Tekla Capital Management LLC. This U.S.-domiciled fund, which commenced operations on February 20, 1992, and was formerly known as H&Q Life Sciences Investors, seeks investment opportunities in publicly traded companies worldwide. Its primary focus lies within the broad life sciences sector, encompassing a diverse range of industries such as biotechnology, pharmaceuticals, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, and medical devices and supplies. The fund also extends its investment purview to include the agriculture and environmental management sectors. It predominantly allocates capital to growth-oriented businesses, particularly those with small market capitalizations. Investment decisions are rooted in rigorous fundamental analysis, which assesses critical factors like a company's market position for its offerings, the acumen of its management team, its technological prowess, and its capability to either self-finance expansion or attract external funding to build its portfolio. The fund's performance is gauged against two key benchmarks: the NASDAQ Biotech Index and the S&P 500 Index.